
RNAC EPS Estimates
Cartesian Therapeutics, Inc.
$6.14
+$0.25(+4.24%)
37
Overall
40
Value
40
Tech
31
Quality
Market Cap
$187.29M
Volume
278.09K
52W Range
$5.60 - $11.00
Target Price
$33.67
RNAC EPS estimates: the consensus estimate for Cartesian Therapeutics, Inc.'s current fiscal year is -$2.19 per share. Quarterly and next-year EPS forecasts, growth estimates and revenue projections follow.
RNAC EPS Estimates
- EPS estimate, current quarter
- $-0.85
- EPS estimate, next quarter
- $-0.75
- EPS estimate, current year
- $-2.19
- EPS estimate, next year
- $-3.25
- EPS growth, 3-year
- -100.00%
| Fiscal year | EPS |
|---|---|
| 2025 | $-5.02 |
| 2024 | $-4.48 |
| 2023 | $-49.80 |
| 2022 | $7.20 |
| 2021 | $-6.60 |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RNAC | $6.14 | +4.2% | 278.09K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cartesian Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW